Viagene Inc. shareholders gained about $31 million when the gene therapy companys merger into Chiron Corp. closed at about a 35 percent premium to the value of the deal when it was announced in April.

CHIR last week announced that it completed the acquisition of VIGN by issuing 915,000 common shares and